oscar

Clinical Guideline

Guideline Number: CG030, Ver. 2

Bioengineered Skin and Soft Tissue Substitutes

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Oscar may delegate utilization management decisions of certain services to third-party delegates, who may develop and adopt their own clinical criteria.

The clinical guidelines are applicable to all commercial plans. Services are subject to the terms, conditions, limitations of a member's plan contracts, state laws, and federal laws. Please reference the member's plan contracts (e.g., Certificate/Evidence of Coverage, Summary/Schedule of Benefits) or contact Oscar at 855-672-2755 to confirm coverage and benefit conditions.

Summary

Injuries and damage to the skin or underlying soft tissue can occur through a number of different mechanisms. Common causes may include severe burns, accidents, surgical procedures, and ulcers (e.g., diabetic or venous stasis ulcers). In most cases, conservative treatment, such as optimizing blood flow, preventing or treating infections, keeping the tissue moist, and clearing any dead tissue is adequate. However, some wounds require more advanced techniques to promote wound healing in the presence of other comorbidities or due to the extent of the damage. In such cases, biologic or synthetic skin/tissue products may be grafted to the wound. These skin/tissue products can provide living cells and/or a scaffold to encourage wound closure, promote tissue regeneration, or provide structural support. They can be "donated" from another site on the patient's body or bioengineered depending the specific indication. Such procedures are often part of a multidisciplinary wound care treatment plan.

This guideline covers the clinical criteria, indications, and exclusions for bioengineered skin and soft tissue substitutes. This document does *not* address cosmetic or reconstructive skin procedures, blood-derived products for chronic wound healing, hyperbaric oxygen therapy, negative pressure wound therapy, suction devices, infrared or electrical stimulation, or other types of wound management.

Certain skin and soft tissue substitutes may be covered as part of medically necessary breast reconstruction as per Oscar Clinical Guideline: Breast Procedures (CG036).

Definitions

"Bioengineered Skin Substitutes," also referred to as "**Human Skin Equivalents (HSE),"** are engineered, "artificial skin" products or combinations of skin products and other materials . They can be acellular or cellular, as defined below, and can be contained within a framework called a matrix, which can be synthetic or natural.

"Cellular Dressing" refers to a bioengineered skin substitute containing at least one layer of live cells (e.g., fibroblasts, keratinocytes, epidermal cells, dermal cells, etc). The cells can be derived from the patient (i.e., autologous), a human donor (i.e., allogeneic), or from another species (i.e., xenographic). They can also be derived from different tissues other than skin, such as placenta, intestine, or synthetic/composite materials. Cellular dressings provide a framework for the patient's own body to begin wound healing as well as other growth factors and cells to facilitate this process.

- Apligraf (Q4101) - a living, bilayered (epidermal and dermal) skin substitute derived from human keratinocytes and fibroblasts
- Dermagraft (Q4106) - a human fibroblast-derived dermal substitute
- Epicel (Q4100) - a cultured epidermal autograft
- Epifix (Q4131) - a multilayer biologic allograft derived from human amniotic membrane
- Grafix Core and Grafix PRIME (Q4132-Q4133) - extracellular matrix containing growth factors designed as allografts with endogenous mesenchymal stem cells; Grafix Core is derived from chorionic placental tissue and Grafix PRIME is derived from the amniotic membrane of placental tissue
- OrCel (Q4100) - a bilayered skin substitute consisting of epidermal keratinocytes and dermal fibroblasts in two layers of bovine collagen
- Theraskin (Q4121) - a biologically active epidermal and dermal skin substitute consisting of cryopreserved human skin allograft, fibroblasts, keratinocytes, and extracellular matrix
- TransCyte (Q4100) - a biosynthetic dressing consisting of allogeneic human dermal fibroblasts

"Acellular Dressing" refers to a bioengineered skin substitute containing matrix or scaffold materials (e.g., collagen, hyaluronic acid) but without any living cells. Acellular matrix provides a foundation for the patient's cells to begin building upon to aid in wound healing.

- Biobrane/Biobrane-L (Q4100) - a biosynthetic wound dressing constructed from a silicon film with nylon impregnated into the dressing
- Cortiva/Allomax/NeoForm (Q4100), Alloderm (Q4116), FlexHD (Q4128)
- Integra Bilayer Matrix Wound Dressing (Q4104), Integra Meshed Bilayer Wound Matrix (C9363), and Integra Dermal Regeneration Template (Q4105) - cross-linked bovine tendon collagen and glycosaminoglycan and a semi-permeable polysiloxane (silicone) layers

- Graftjacket Regenerative Tissue Matrix (Q4107) - a cadaveric dermal and epidermal skin substitute
- Oasis Wound Matrix (Q4102) - an extracellular matrix material derived from the submucosal layer of porcine small intestine

"Grafting" is when a material (whether organic or synthetic) is transplanted to cover an injury or wound. There are several graft types:

- **"Autologous"** grafting (e.g. autograft) refers to a graft derived from the patient's own skin/tissue, and can be referred to as partial- or split-thickness depending on how it is harvested
- **"Allogeneic"** grafting (e.g. allograft) refers to a graft derived from another human other than the patient (e.g. cadaver)
- **"Xenographic"** grafting refers to a graft derived from non-human organisms (e.g., cows, pigs, etc.)
- "**Synthetic**" grafting refers to a graft that is derived from man-made materials
- **"Composite"** grafting refers to a graft derived from various materials or organisms that can be interlinked to create a final product, such as a combination of human cells and synthetic matrix

"Epidermolysis Bullosa (EB)" is a rare disease characterized by fragile skin and recurrent blisters resulting from minor irritation or trauma, typically presenting in early childhood. The resulting blisters may form large, painful wounds that resemble severe burns, and may require extensive grafting.

Clinical Indications and Coverage

General Coverage Criteria

In addition to the product-specific criteria outlined below, **ALL** of the following criteria must be met:

1. The procedure is performed by a licensed practitioner per state and federal law; ***and***
2. Patients using tobacco products have received cessation counseling and been informed of the impact of smoking on surgical outcomes prior to the procedure; ***and***
3. Medical records document **ALL** of the following:
    a. Medical necessity for the skin/tissue substitute; ***and***
    b. Wound characteristics, including the size, location, depth, underlying conditions; ***and***
    c. Previous methods, response, and duration of conservative therapy; ***and***
    d. Full treatment plan that accompanies the bioengineered skin/tissue substitute.
4. The duration and frequency of the treatment plan is ordered as follows:
    a. Treatment is limited to one initial application; ***and***

b. Additional applications may occur at a minimum of 1 week intervals up to a maximum of 12 weeks (specific number of treatments may vary) *and* only when there is evidence of wound healing (e.g., reduced ulcer size, increasing epithelialization).

Product-Specific Coverage Criteria

Biobrane/Biobrane-L (Q4100)

Biobrane/Biobrane-L (Q4100) is considered medically necessary and covered when **ONE** of the following criteria are met:

1. Biobrane: For the temporary covering of superficial, partial-thickness thermal injury; ***or***
2. Biobrane-L: Covered when the criteria for Biobrane are met **AND** the dressing is used as an adjunct to a meshed autograft.

Epicel (Q4100)

Epicel (Q4100) is considered medically necessary per FDA-approved Humanitarian Device Exemption (HDE) and is covered when **ONE** of the following criteria are met:

1. For deep-dermal or full-thickness burns reaching a total body surface area (BSA) ≥ 30%; ***or***
2. For use in conjunction with split-thickness autografts or alone in patients who are not candidates for autografting given the severity and/or extent of the thermal injury or the instability of the current overall condition.

OrCel (Q4100)

OrCel (Q4100) is considered medically necessary and covered when **ONE** of the following criteria are met:

1. To close and heal wounds in children with dystrophic epidermolysis bullosa who are undergoing hand surgery, including donor sites; ***or***
2. To be applied to donor sites in patients who have been burned and required autografting.

TransCyte (Q4100)

TransCyte (Q4100) is considered medically necessary and covered when **ONE** of the following criteria are met:

1. For deep partial- and full-thickness thermal injury (e.g. second and third degree burns) after surgical excision has been performed, in patients who need temporary wound covering prior to autografting; ***or***
2. For mid-dermal burns or those of an indeterminate depth that are expected to heal without autografting.

Allomax/Cortiva/NeoForm (Q4100), Alloderm (Q4116), or FlexHD (Q4128)

Allomax/Cortiva/NeoForm (Q4100), Alloderm (Q4116), or FlexHD (Q4128) is considered medically necessary and covered when the following criteria is met:

1. For use in patients undergoing breast reconstructive surgery when used in conjunction with a covered, medically necessary breast reconstructive surgery.

Apligraf (Q4101), Oasis Wound Matrix (Q4102), or Theraskin (Q4121)

Apligraf (Q4101), Oasis Wound Matrix (Q4102), or Theraskin (Q4121) is considered medically necessary and covered when the following criteria are met:

1. Apligraf is not being used in conjunction with Dakin's solution, chlorhexidine, polymyxin/nystatin, or any other cytotoxic solution due to breakdown and loss of effectiveness as demonstrated in clinical studies; ***and***
2. For diabetic foot ulcers, when the following characteristics are present:
    a. Full thickness (e.g. extends through the dermis) neuropathic diabetic foot ulcer; ***and***
    b. The ulcer does not expose bone, tendon, muscle, or joint capsule; ***and***
    c. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
        i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
        ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
        iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.
    d. Appropriate conventional therapy has failed or been ineffective, as defined by standard dressing changes, debridement as necessary, and off-loading of pressure/weight
        i. For Apligraf, a minimum of 3 weeks; ***or***
        ii. For Oasis Wound Matrix or Theraskin, a minimum of 4 weeks.
    e. The patient has a current diagnosis of type 1 or type 2 diabetes, and the hemoglobin A1C is less than 12%.
3. For venous insufficiency skin ulcers, when the following characteristics are present:
    a. Ulcer must be chronic, non-infected, partial- or full-thickness and due to venous insufficiency; ***and***
    b. A minimum of *4 weeks* of appropriate conventional therapy has failed or been ineffective; ***and***
    c. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
        i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
        ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
        iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.

d. Conventional therapy must have included standard therapeutic compression.

Dermagraft (Q4106)

Dermagraft (Q4106) is considered medically necessary and covered when the following criteria are met:

1. Dermagraft is not being used in conjunction with Dakin's solution, chlorhexidine, polymyxin/nystatin, or any other cytotoxic solution due to breakdown and loss of effectiveness as demonstrated in clinical studies; ***and***
2. Dermagraft is not ordered for patients under the age of 18, pregnant women, patients receiving immunosuppressive therapy (e.g. steroids, chemotherapy), or patients with ulcers overlying Charcot's deformity; ***and***
3. Treatment strictly adheres to FDA labeling guidelines, as documented by the 24-step procedure; ***and***
4. For dystrophic epidermolysis bullosa wounds; ***or***
5. For diabetic foot ulcers, when the following characteristics are present:
    a. Full thickness (e.g. extends through the dermis) neuropathic diabetic foot ulcer; ***and***
    b. The ulcer does not expose bone, tendon, muscle, or joint capsule; ***and***
    c. The ulcer has no evidence of infection or a sinus tract; ***and***
    d. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
        i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
        ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
        iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.
    e. A minimum of 6 weeks of appropriate conventional therapy has failed or been ineffective, as defined by standard dressing changes, debridement as necessary, and off-loading of pressure/weight; ***and***
    f. The patient has a current diagnosis of type 1 or type 2 diabetes, and the hemoglobin A1C is less than 12%.

Epifix (Q4131)

Epifix (Q4131) is considered medically necessary and covered when the following criteria are met:

1. The ulcer has no evidence of infection or malignancy; ***and***
2. The patient does not have an autoimmune connective tissue disease; ***and***
3. The patient is not being treated with radiation, chemotherapy, or COX-2 inhibitors; ***and***
4. For diabetic foot ulcers, when the following characteristics are present:
    a. Full thickness (e.g. extends through the dermis) neuropathic diabetic foot ulcer; ***and***
    b. The ulcer does not expose bone, tendon, muscle, or joint capsule; ***and***

c. A minimum of 4 weeks, and a maximum of 52 weeks, of appropriate conventional therapy has failed or been ineffective, as defined by standard dressing changes, debridement as necessary, and off-loading of pressure/weight: ***and***
d. The patient has a current diagnosis of type 1 or type 2 diabetes, and the hemoglobin A1C is less than 12%; ***and***
e. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
    i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
    ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
    iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.
f. The wound is between 1cm^2 and 25cm^2.

5. For venous insufficiency skin ulcers, when the following characteristics are present:
    a. Ulcer must be chronic, non-infected, partial- or full-thickness and due to venous insufficiency; ***and***
    b. A minimum of *4 weeks* of appropriate conventional therapy has failed or been ineffective; ***and***
    c. Conventional therapy must have included at least 14 days of standard therapeutic compression; ***and***
    d. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
        i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
        ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
        iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.
    e. The wound is between 2cm^2 and 20cm^2; ***and***
    f. If the patient has diabetes, the hemoglobin A1C is less than 10%; ***and***
    g. The ulcer is not on the dorsum of the foot or at least 50% of the ulcer is below the malleolus.

Grafix Core and Grafix PRIME (Q4132-Q4133) or Graftjacket Regenerative Tissue Matrix (Q4107)
Grafix Core and Grafix PRIME (Q4132-Q4133) or Graftjacket Regenerative Tissue Matrix (Q4107) is considered medically necessary and covered when the following criteria are met:

1. For Grafix Core and Grafix PRIME, the ulcer has no evidence of infection; ***and***
2. For Graftjacket Regenerative Tissue Matrix, treatment is limited to **ONE** application; ***and***
3. For diabetic foot ulcers, when the following characteristics are present:
    a. Full thickness (e.g. extends through the dermis) neuropathic diabetic foot ulcer; ***and***
    b. The ulcer does not expose bone, tendon, muscle, or joint capsule; ***and***

c. A minimum of 4 weeks of appropriate conventional therapy has failed or been ineffective, as defined by standard dressing changes, debridement as necessary, and off-loading of pressure/weight: ***and***
d. The patient has a current diagnosis of type 1 or type 2 diabetes, and the hemoglobin A1C is less than 12%; ***and***
e. The patient must have adequate circulation to the affected extremity, and may be defined by**:**
    i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
    ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
    iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.

Integra Bilayer Matrix Wound Dressing (Q4104) or Integra Meshed Bilayer Wound Matrix (C9363) or Integra Dermal Regeneration Template (Q4105)

Integra Bilayer Matrix Wound Dressing (Q4104) or Integra Meshed Bilayer Wound Matrix (C9363) or Integra Dermal Regeneration Template (Q4105) are considered medically necessary and covered when the following criteria are met:

1. Hemostasis must be obtained prior to application, as blood products may interfere with application; ***and***
2. Integra Bilayer Matrix Wound Dressing or Integra Meshed Bilayer Wound Matrix are covered for deep partial- and full-thickness thermal injury (e.g. second and third degree burns), when applied on the day of excision and when **ONE** of the following characteristics are present:
    a. There is inadequate remaining skin to perform autografting; ***or***
    b. The patient is too ill for further autografting.
3. Integra Dermal Regeneration Template is covered for diabetic foot ulcers when **ALL** of the following characteristics are present:
    a. Full thickness (e.g. extends through the dermis) neuropathic diabetic foot ulcer; ***and***
    b. The ulcer does not expose bone, tendon, muscle, or joint capsule; ***and***
    c. The patient must have adequate circulation to the affected extremity, as defined by**:**
        i. Transcutaneous oxygen test (TcPO2) ≥30 mmHg; ***or***
        ii. Ankle-brachial index (ABI) between 0.7 and 1.2; ***or***
        iii. Triphasic or biphasic doppler arterial waveforms at the ankle of the affected leg.
    d. A minimum of *6 weeks* of appropriate conventional therapy has failed or been ineffective, as defined by standard dressing changes, debridement as necessary, and off-loading of pressure/weight; ***and***
    e. The patient has a current diagnosis of type 1 or type 2 diabetes, and the hemoglobin A1C is less than 12%.

Coverage Exclusions

Applications beyond 12 weeks are not considered medically necessary and are therefore not covered. Retreatment of a successfully treated, healed ulcer is generally not covered.

Skin/tissue substitutes or wound care treatments ordered for any indication not listed in the coverage criteria are considered investigational and/or experimental, and thus **NOT** medically necessary. The following skin/tissue substitutes or other wound care treatments are considered investigational and/or experimental, and thus **NOT** medically necessary (not all inclusive):

Affinity™	AlloMax™	AlloMend™
Allopatch HD™	Alloskin AC	AlloSkin RT
AlloWrap®	AlloWrap™ Dry	AlloWrap™ DS
Alphaplex™ with MariGen Omega3™	AmnioBand (see Guardian)	AmnioCare®
AmnioClear®	AmnioExcel™	AmnioFix™
AmnioGraft®	Amniomatrix™	AmnioMTM™
AmnioShield®	Aongen™ Collagen Matrix	Architect Extracellular Matrix™
Artelon®	Arthroflex™	Atlas Wound Matrix
Avance® Nerve Graft	Avaulta Plus™	AxoGuard® nerve connector
AxoGuard® nerve protector	Belladerm®	Bio-ConneKt®
BioDDryFlexv® Resorbable Adhesion Barrier	BioDExCel™	BioDfactor™
BioDfence™	BioDOptix™	BioFiber™
BioVance®	CellerateRX®	CG CryoDerm™
CLARIX™ 100 Quick-Peel Wound Matrix	CLARIX™ 1k	CLARIX™ FLO

CollaFix™	CollaGUARD®	Collamend™
CollaSorb™	CollaWound™	Collexa®
Conexa™	CorMatrix®	C-QUR™
CRXa™	CryoSkin®	Cuffpatch™
Cymetra®	DeNovo® NT Graft	Dermacell ™
Dermadapt™ Wound Dressing	Dermamatrix®	DermaPure™
DermaSpan™	Dermavest™	Dermavest 2™
DressSkin™	Duraform™	Duragen™ Plus
Duragen® XS	DuraMatrix™	Durepair® Regeneration Matrix
Endobon® Xenograft Granules	Endoform™	ENDURAgen™
EpiDex®	EpiFix™, particulate or injectable form	Excellagen®
E-Z Derm™	FloGraft™	FortaDerm™ Wound Dressing
Fortiva™Porcine Dermis	Gammagraft™	GORE BIO-A® Fistula Plug
Graftjacket™ Xpress injectable	GraftRope™	Guardian (see AmnioBand)
HA Absorbent Wound Dressing	Helicoll	hMatrix®
Hyalomatrix®	Inforce®	Integra™ Matrix Wound Dressing
InteguPly™	Jaloskin®	LiquidGen™
MariGen Omega3	Matriderm®	Matristem®
Matrix HD™	Medeor™	MediHoney®
Mediskin®	Memoderm™	Menaflex™ Collagen Meniscus Implant
Meso BioMatrix™	Nanofactor™ Flow	Nanofactor™ Membrane

NEOX® 100 Quick-Peel Wound Matrix	NEOX® 1k Wound Matrix	NEOX®FLO
Neuragen®	NeuraWrap™	Neuroflex™
NeuroMatrix™	NeuroMend™	NuCel®
NuShield®	OrthADAPT™	OsseoGuard®
Ovation®	PalinGen Flow™	PalinGen SportFlow™
Pelvicol®	Pelvisoft®	Peri-Guard® Repair Patch
Peri-Strips Dry®	Perlane®	Permacol™
Phasix Mesh™	Preclude® Pericardial Membrane	Preclude® Vessel Guard
Primatrix ™	PTFE felt	Puracol®
Puros® Dermis	PX50® and X50® Plus	Repliform®
Repriza™	Restore® Orthobiologic Soft Tissue Implant	Restylane®
Revitalon™	Seamguard®	SERI® Surgical Scaffold
SIS Wound Dressing II	SJM™ Pericardial Patch	SportMatrix
SportMesh™	SS Matrix™	Stimulen™ Collagen
StrataGraft®	Strattice™	Suprathel®
SurgiMend®	Surgisis® (including Surgisis® AFP™ Anal Fistula Plug, Surgisis® Gold™ Hernia Repair Grafts, and Surgisis®Biodesign™)	Talymed ™
TenoGlide™	TenSIX™	TheraForm™ Standard/Sheet
TissueMend®	Tornier® BioFiber Absorbable Biological Scaffold	TranzGraft®

Tutomesh™ Fenestrated Bovine Pericardium	Tutopatch™ Bovine Pericardium	Unite™
Vascu-Guard®	Veritas® Collagen Matrix	WoundEx®
XCM Biologic™	Xelma®	XenMatrix™
XenMatrix™ Surgical Graft	XenoSure® Biolog	X-Repair
Xwrap™ (Hydro, DRY, and ECM		

Applicable Billing Codes (CPT/HCPCS/ICD-10 Codes)

CPT/HCPCS Codes covered if criteria are met:	
Code	*Description*
C5271 - C5274	Application of low cost skin substitute graft to trunk, arms, legs
C5275 - C5278	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits
C9363	Skin substitute, Integra Meshed Bilayer Wound Matrix, per square centimeter
Q4100	Skin substitute, not otherwise specified (Must explain specific use and documentation) - Use for billing: TransCyte™, Orcel®, Biobrane Biosynthetic Dressing®, Epicel®, AlloMax, DermaMatrix™
Q4101	Apligraf, per sq cm
Q4102	Oasis Wound Matrix, per sq cm
Q4104	Integra Bilayer Matrix Wound Dressing (BMWD), per sq sm
Q4105	Integra Dermal Regeneration Template (DRT), per sq cm
Q4106	Dermagraft, per sq cm
Q4107	Graftjacket, per sq cm
Q4116	Alloderm, per square centimeter
Q4121	TheraSkin, per sq cm
Q4128	FlexHD, per sq cm
Q4131	Epifix, per square centimeter
Q4132	Grafix core, per sq cm

Q4133	Grafix prime, per sq cm
Q4182	Transcyte, per square centimeter
ICD-10 codes covered if criteria are met for Biobrane/Biobrane-L and Transcyte (Q4100):	
T20.011-T25.799	Burns
ICD-10 codes covered if criteria are met for Epicel (Q4100):	
T20.011-T25.799,T31.30-T31.99, T32.30-T32.99	Burns
ICD-10 codes covered if criteria are met for OrCel (Q4100):	
Q81.2	Epidermolysis bullosa dystrophica
T20.011-T25.799	Burns
ICD-10 codes covered if criteria are met for Allomax/Cortiva/NeoForm (Q4100), Alloderm (Q4116), or **FlexHD (Q4128):**	
C50.011 - C50.929	Malignant neoplasm of breast
C79.81	Secondary malignant neoplasm of breast
D05.00 - D05.92	Carcinoma in situ of breast
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z15.02	Genetic susceptibility to malignant neoplasm of ovary
Z80.3	Family history of malignant neoplasm of breast
Z80.41	Family history of malignant neoplasm of ovary
Z85.3	Personal history of malignant neoplasm of breast
Z90.10 - Z90.13	Acquired absence of breast and nipple
Z92.3	Personal history of irradiation
ICD-10 codes covered if criteria are met for Apligraf (Q4101), Oasis Wound Matrix (Q4102), or **Theraskin (Q4121):**	
E08.621	Diabetes mellitus due to underlying condition with foot ulcer
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer

E11.621	Type 2 diabetes mellitus with foot ulcer
E13.621	Other specified diabetes mellitus with foot ulcer
I83.001 - I83.029	Varicose veins of lower extremities with ulcer
I83.201 - I83.229	Varicose veins of lower extremities with ulcer and inflammation
I87.311 - I87.319	Chronic venous hypertension (idiopathic) with ulcer
I87.331 - I87.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation
ICD-10 codes covered if criteria are met for Dermagraft (Q4106):	
E08.621	Diabetes mellitus due to underlying condition with foot ulcer
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer
E11.621	Type 2 diabetes mellitus with foot ulcer
E13.621	Other specified diabetes mellitus with foot ulcer
Q81.2	Epidermolysis bullosa dystrophica
ICD-10 codes covered if criteria are met for Epifix (Q4131), Grafix Core and Grafix PRIME (Q4132-Q4133) or **Graftjacket Regenerative Tissue Matrix (Q4107):**	
E08.621, E09.621, E10.621, E11.621, E13.621	Diabetes mellitus
ICD-10 codes covered if criteria are met for Integra Bilayer Matrix Wound Dressing (Q4104) or **Integra Meshed Bilayer Wound Matrix (C9363)** or **Integra Dermal Regeneration Template (Q4105):**	
E08.621, E09.621, E10.621, E11.621, E13.621	Diabetes mellitus
T20.011-T25.799	Burns

CPT/HCPCS codes *not* covered:	
Code	*Description*
A6196 - A6199	Alginate or other fiber gelling dressing, wound cover, sterile
C9250	Human plasma fibrin sealant, vapor-heated, solvent-detergent (Artiss), 2ml

C9352	Microporous collagen implantable tube (NeuraGen Nerve Guide), per cm length
C9353	Microporous collagen implantable slit tube (NeuraWrap Nerve Protector), per cm length
C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm
C9356	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (Tenoglide Tendon Protector Sheet), per square centimeter
C9358	Dermal substitute, native, non-denatured collagen (SurgiMend Collagen Matrix), per 0.5 square centimeters
C9360	Dermal substitute, native, non-denatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 square centimeters
C9361	Collagen matrix nerve wrap (NeuroMend Collagen Nerve Wrap), per 0.5 cm length
C9364	Porcine implant, Permacol, per square centimeter
G0428	Collagen meniscus implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold, Menaflex)
Q4103	Oasis Burn Matrix, per sq cm
Q4108	Integra Matrix Wound Dressing
Q4110	PriMatrix, per sq cm
Q4111	GammaGraft, per sq cm
Q4112	Cymetra, injectable, 1 cc
Q4113	GRAFTJACKET XPRESS, injectable, 1cc
Q4114	Integra Flowable Wound Matrix, injectable, 1 cc
Q4115	AlloSkin, per square centimeter
Q4117	HYALOMATRIX, per sq cm
Q4118	MatriStem micromatrix, 1 mg
Q4119	MatriStem wound matrix, per sq cm
Q4122	DermACELL, per sq cm
Q4123	AlloSkin RT, per square centimeter
Q4124	OASIS ultra tri-layer wound matrix, per sq cm
Q4125	Arthroflex, per sq cm

Q4126	MemoDerm, DermaSpan, TranZgraft or IntéguPly, per square centimeter
Q4127	Talymed, per sq cm
Q4129	Unite biomatrix, per sq cm
Q4130	Strattice, per sq cm
Q4134	hMatrix, per sq cm
Q4135	Mediskin, per sq cm
Q4136	E-Z Derm, per sq cm
Q4137	Amnioexcel or biodexcel, per sq cm
Q4138	Biodfence dryflex, per sq cm
Q4139	Amniomatrix or bioDMatrix, injectable, 1 cc
Q4140	Biodfence, per sq cm
Q4141	AlloSkin AC, per square centimeter
Q4142	XCM biologic tissue matrix, per sq cm
Q4143	Repriza, per sq cm
Q4145	Epifix, injectable, 1 mg
Q4147	Architect, architect PX, or architect FX, extracellular matrix, per sq cm
Q4148	NEOX 1K, per square centimeter
Q4149	Excellagen, 0.1 cc
Q4150	Allowrap DS or dry, per sq cm
Q4151	Amnioband or guardian, per sq cm
Q4152	Dermapure, per sq cm
Q4153	Dermavest and Plurivest, per sq cm
Q4154	Biovance, per sq cm
Q4155	Neoxflo or clarixflo 1 mg
Q4156	Neox 100, per sq cm
Q4157	Revitalon, per sq cm
Q4158	Marigen, per sq cm
Q4159	Affinity, per sq cm
Q4160	Nushield, per square centimeter

Q4161	Bio-connekt wound matrix, per square centimeter
Q4162	Amniopro flow, Bioskin flow, Biorenew flow, Woundex flow, Amniogen-A, Amniogen-C, 0.5 cc
Q4163	Amniopro, Bioskin, Biorenew, Woundex, Amniogen-45, Amniogen-200, per square centimeter
Q4164	Helicoll, per square centimeter
Q4165	Keramatrix, per square centimeter
Q4166	Cytal, per square centimeter[Cytal Burn Matrix, Cytal Wound Matrix]
Q4167	Truskin, per square centimeter
Q4168	Amnioband, 1 mg
Q4169	Artacent wound, per square centimeter
Q4170	Cygnus, per square centimeter
Q4171	Interfyl, 1 mg
Q4172	Puraply or Puraply AM, per square centimeter
Q4173	Palingen or Palingen XPlus, per square centimeter
Q4174	Palingen or Promatrix, 0.36 mg per 0.25 cc
Q4175	Miroderm, per square centimeter
Q4178	Floweramniopatch, per square centimeter
Q4181	Amnio wound, per square centimeter
Q4100	Skin substitute, not otherwise specified *(use assigned code for covered product))*
S9055	Procuren or other growth factor preparation to promote wound healing

References

1. Al-Abed YA, Ayers J, Ayantunde A, Praveen BV. Safety and efficacy of Permacol injection in the treatment of fecal incontinence. Ann Coloproctol. 2016;32(2):73-78.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013; 36(Suppl 1):S11-S66.

3. Angrisani L, Lorenzo M, Borrelli V, et al. The use of bovine pericardial strips on linear stapler to reduce extraluminal bleeding during laparoscopic gastric bypass: Prospective randomized clinical trial. Obes Surg. 2004;14(9):1198-1202.
4. Armstrong DG, Meyr AJ. Basic principles of wound management. UpToDate [serial online]. Waltham, MA: UpToDate; reviewed November 2013.
5. Athavale SM, Phillips S, Mangus B, et al. Complications of AlloDerm and DermaMatrix for parotidectomy reconstruction. Head Neck. 2012; 34(1):88-93.
6. Austin RE, Merchant N, Shahrokhi S, Jeschke MG. A comparison of Biobrane™ and cadaveric allograft for temporizing the acute burn wound: Cost and procedural time. Burns. 2015;41(4):749-753.
7. Barber C, Watt A, Pham C, et al. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes. J Wound Care. 2008;17(12):517-527.
8. Barber FA, Burns JP, Deutsch A, et al. A prospective, randomized evaluation of acellular human dermal matrix augmentation for arthroscopic rotator cuff repair. Arthroscopy. 2012; 28(1):8-15.
9. Barret JP, Dziewulski P, Ramzy PI, et al. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg. 2000; 105(1):62-65.
10. Becker S, Saint-Cyr M, Wong C, et al. AlloDerm versus DermaMatrix in immediate expander-based breast reconstruction: a preliminary comparison of complication profiles and material compliance. Plast Reconstr Surg. 2009; 123(1):1-6.
11. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001;2(5):305-313.
12. Blackman E, Moore C, Hyatt J, et al. Topical wound oxygen therapy in the treatment of severe diabetic foot ulcers: A prospective controlled study. Ostomy Wound Manage. 2010;56(6):24-31.
13. Bond E, Barrett S, Pragnell J. Successful treatment of non-healing wounds with Xelma(R). Br J Nurs. 2010;18(22):1404-1409.
14. Bowers CA, Brimley C, Cole C, et al. AlloDerm for duraplasty in Chiari malformation: Superior outcomes. Acta Neurochir (Wien). 2015;157(3):507-511
15. Boyapati L, Wang HL. The role of platelet-rich plasma in sinus augmentation: A critical review. Implant Dent. 2006;15(2):160-170.
16. Boyd WD, Johnson WE 3rd, Sultan PK, et al. Pericardial reconstruction using an extracellular matrix implant correlates with reduced risk of postoperative atrial fibrillation in coronary artery bypass surgery patients. Heart Surg Forum. 2010; 13(5):E311-E316.
17. Bradley M, Cullum N, Nelson EA, et al. Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds. Health Tech Assess. 1999;(17 Pt 2):1-35.

18. Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. Crit Care Med. 2007; 35(11):2615-2623.
19. Brigido SA, Boc SF, Lopez RC. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics. 2004; 27(1 Suppl):s145-149.
20. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006; 3(3):181-187.
21. Brooke A, Mesa J, Uluer M, et al. Complications in tissue expander breast reconstruction: a comparison of AlloDerm, DermaMatrix, and FlexHD acellular inferior pole dermal slings. Ann Plast Surg. 2012; 69(4):347-349.
22. Brooke S, Mesa J, Uluer M, et al. Complications in tissue expander breast reconstruction: a comparison of AlloDerm, DermaMatrix, and FlexHD acellular inferior pole dermal slings. Ann Plast Surg. 2012; 69(4):347-349.
23. Brosious JP, Wong N, Fowler G, et al. Evaluation of AlloMax acellular dermal matrix for objective collagen deposition. J Reconstr Microsurg. 2014;30(1):31-34.
24. Buchberger B, Follmann M, Freyer D, et al. The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): A health technology assessment (HTA). Exp Clin Endocrinol Diabetes. 2011;119(8):472-479.
25. Byrnes MC, Irwin E, Carlson D, et al. Repair of high-risk incisional hernias and traumatic abdominal wall defects with porcine mesh. Am Surg. 2011;77(2):144-150.
26. Cahan AC, Palaia DA, Rosenberg M, Bonanno PC. The aesthetic mastectomy utilizing a non-nipple-sparing portal approach. Ann Plast Surg. 2011; 66(5):424-428.
27. Capito AE, Tholpady SS, Agrawal H, et al. Evaluation of host tissue integration, revascularization, and cellular infiltration within various dermal substrates. Ann Plast Surg. 2012;68(5):495-500.
28. Caravaggi C, Francesco Grigoletto M, Scuderi N. Wound bed preparation with a dermal substitute (Hyalomatrix® PA) facilitates re-epithelialization and haling: Results of a multicenter, prospective, observational study on complex chronic ulcers: The FAST Study. Wounds. 2011;8(23):228-235.
29. Carlson M, Faria K, Shamis Y, et al. Epidermal stem cells are preserved during commercial-scale manufacture of a bilayered, living cellular construct (Apligraf®). Tissue Eng Part A. 2011;17(3-4):487-493.
30. Carsin H, Ainaud P, Le Bever H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns. 2000;26(4):379-387.
31. Cervigni M, Natale F, La Penna C, et al. Collagen-coated polypropylene mesh in vaginal prolapse surgery: An observational study. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):223-227.

32. Chadwick P, Acton C. The use of amelogenin protein in the treatment of hard-to-heal wounds. Br J Nurs. 2009;18(6):S22, S24, S26, passim.
33. Chalmers RT, Darling Iii RC, Wingard JT, et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg. 2010;97(12):1784-1789.
34. Chauviere MV, Schutter RJ, Steigelman MB, et al. Comparison of AlloDerm and AlloMax tissue incorporation in rats. Ann Plast Surg 2014;73(3):282-285.
35. Chavarriaga LF, Lin E, Losken A, et al. Management of complex abdominal wall defects using acellular porcine dermal collagen. Am Surg. 2010;76(1):96-100.
36. Cheng A, Saint-Cyr M. Comparison of different ADM materials in breast surgery. Clin Plast Surg. 2012;39(2):167-175.
37. Cole PD, Stal D, Sharabi SE, et al. A comparative, long-term assessment of four soft tissue substitutes. Aesthet Surg J. 2011;31(6):674-681.
38. Connolly RJ. Evaluation of a unique bovine collagen matrix for soft tissue repair and reinforcement. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(Suppl 1):S44-S47.
39. Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014;23(10):465-474,
40. Craft RO, May JW Jr. Staged nipple reconstruction with vascularized SurgiMend acellular dermal matrix. Plast Reconstr Surg. 2011;127(6):148e-149e.
41. Dahlgren E, Kjølhede P.; RPOP-PELVICOL Study Group. Long-term outcome of porcine skin graft in surgical treatment of recurrent pelvic organ prolapse. An open randomized controlled multicenter study. Acta Obstet Gynecol Scand. 2011; 90(12):1393-1401.
42. Dantzer E, Braye FM. Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. Br J Plast Surg. 2001; 54(8):659-664.
43. Dapri G, Cadière GB, Himpens J. Reinforcing the staple line during laparoscopic sleeve gastrectomy: Prospective randomized clinical study comparing three different techniques. Obes Surg. 2010;20(4):462-467.
44. de la Portilla F, Rada R, Vega J, et al. Transanal rectocele repair using linear stapler and bioabsorbable staple line reinforcement material: Short-term results of a prospective study. Dis Colon Rectum. 2010;53(1):88-92.
45. De SK, Reis ED, Kerstein MD. Wound treatment with human skin equivalent. J Am Podiatr Med Assoc. 2002;92(1):19-23.
46. DeCarbo WT. Special segment: soft tissue matrices--Apligraf bilayered skin substitute to augment healing of chronic wounds in diabetic patients. Foot Ankle Spec. 2009;2(6):299-302.
47. Demling RH, DeSanti L. Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns. 1999; 25(3):256-261.

48. Derwin KA, Baker AR, Spragg RK, et al. Commercial extracellular matrix scaffolds for rotator cuff tendon repair. Biomechanical, biochemical, and cellular properties. J Bone Joint Surg Am. 2006;88(12):2665-2672.
49. DiDomenico L, Emch KJ, Landsman AR, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds. 2011; 23(7):184-189.
50. Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68-70, 72, 74.
51. Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23(6):891-900.
52. Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf, a human skin equivalent. Cutis. 1998;62(1 Suppl):1-8.
53. Edmonds M; European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8(1):11-18.
54. Edmonds ME, Foster AV, McColgan M. 'Dermagraft': A new treatment for diabetic foot ulcers. Diabet Med 1997;14:1010-1011.
55. Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006;12(9):2407-2424.
56. El-Khatib HA, Hammouda A, Al-Ghol A, et al. Aldehyde-treated porcine skin versus biobrane as biosynthetic skin substitutes for excised burn wounds: Case series and review of the literature. Ann Burns Fire Disasters. 2007;20(2):78-82.
57. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: A review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006;118(6):147e-159
58. Epstein NE. Dural repair with four spinal sealants: Focused review of the manufacturers' inserts and the current literature. Spine J. 2010;10(12):1065-1068.
59. Espinosa-de-los-Monteros A, de la Torre JI, Marrero I, et al. Utilization of human cadaveric acellular dermis for abdominal hernia reconstruction. Ann Plast Surg. 2007; 58(3):264-267.
60. Everts PA, Knape JT, Weibrich G, et al. Platelet-rich plasma and platelet gel: A review. J Extra Corpor Technol. 2006;38(2):174-187.
61. Faga A, Nicoletti G, Brenta F, et al. Hyaluronic acid three-dimensional scaffold for surgical revision of retracting scars: A human experimental study. Int Wound J. 2013;10(3):329-335.
62. Fahey C. Experience with a new human skin equivalent for healing venous leg ulcers. J Vasc Nurs. 1998;16(1):11-15.

63. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human skin equivalent investigators group. Arch Dermatol. 1998;134(3):293-300.
64. Farole A, Jamal BT. A bioabsorbable collagen nerve cuff (NeuraGen) for repair of lingual and inferior alveolar nerve injuries: a case series. J Oral Maxillofac Surg. 2008; 66(10):2058-2062.
65. Feldman DL, Rogers A, Karpinski RH. A prospective trial comparing Biobrane, Duoderm and xeroform for skin graft donor sites. Surg Gynecol Obstet. 1991; 173(1):1-5.
66. Fleischli JG, Laughlin TJ, Fleischli JW. Equine pericardium collagen wound dressing in the treatment of the neuropathic diabetic foot wound: A pilot study. J Am Podiatr Med Assoc. 2009;99:301-305.
67. Forbes J, Fetterolf DE. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care. 2012; 21(6):290, 292, 294-296.
68. Foster K, Greenhalgh D, Gamelli R et al; FS 4IU VH S/D Clinical Study Group. Efficacy and safety of a fibrin sealant for adherence of autologous skin grafts to burn wounds: Results of a phase 3 clinical study. J Burn Care Res. 2008;29(2):293-303.
69. Frykberg RG, Cazzell SM, Arroyo-Rivera J, et al. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: An interim analysis. J Wound Care. 2016;25 Suppl 7:S18-S25.
70. Frykberg RG, Gibbons GW, Walters JL, et al. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: Positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2016 Aug 3.
71. Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Adv Skin Wound Care. 2015;28(1):17-20.
72. Gamboa-Bobadilla GM. Implant breast reconstruction using acellular dermal matrix. Ann Plast Surg. 2006; 56(1):22-25.
73. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19(4):350-354.
74. Gerding RL, Emerman CL, Effron D, et al. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. Ann Emerg Med. 1990; 19(2):121-124.
75. Gerdisch MW, Shea RJ, Barron MD. Clinical experience with CorMatrix extracellular matrix in the surgical treatment of mitral valve disease. J Thorac Cardiovasc Surg. 2014;148(4):1370-1378.
76. Giordano P, Pullan RD, Ystgaard B, et al. The use of an acellular porcine dermal collagen implant in the repair of complex abdominal wall defects: A European multicentre retrospective study. Tech Coloproctol. 2015;19(7):411-417.

77. Giordano P, Sileri P, Buntzen S, et al. A prospective multicentre observational study of Permacol collagen paste for anorectal fistula: Preliminary results. Colorectal Dis. 2016;18(3):286-294.
78. Glasberg SB, D'Amico RA. Use of regenerative human acellular tissue (AlloDerm) to reconstruct the abdominal wall following pedicle TRAM flap breast reconstruction surgery. Plast Reconstr Surg. 2006; 118(1):8-15.
79. Govindaraj S, Cohen M, Genden EM, et al. The use of acellular dermis in the prevention of Frey's syndrome. Laryngoscope. 2001; 111(11 Pt 1):1993-1998.
80. Greenwood JE. A randomized, prospective study of the treatment of superficial partial-thickness burns: AWBAT-S versus Biobrane. Eplasty. 2011;11:e10.
81. Greer N, Foman NA, MacDonald R, et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: A systematic review. Ann Intern Med. 2013;159(8):532-542.
82. Guo Y, Chen G, Tian G, Tapia C. Sensory recovery following decellularized nerve allograft transplantation for digital nerve repair. J Plast Surg Hand Surg. 2013;47(6):451-453.
83. Gupta AK, Hug K, Berkoff DJ, et al. Dermal tissue allograft for the repair of massive irreparable rotator cuff tears. Am J Sports Med. 2012; 40(1):141-147.
84. Guzman EA, Nelson RA, Kim J, et al. Increased incidence of pancreatic fistulas after the introduction of a bioabsorbable staple line reinforcement in distal pancreatic resections. Am Surg. 2009;75(10):954-957.
85. Hankin CS, Knispel J, Lopes M, et al. Clinical and cost efficacy of advanced wound care matrices for venous ulcers. J Manag Care Pharm. 2012;18(5):375-384.
86. Hansbrough JF, Mozingo DW, Kealey GP, et al. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18(1 Pt 1):43-51.
87. Harth KC, Rosen MJ. Major complications associated with xenograft biologic mesh implantation in abdominal wall reconstruction. Surg Innov. 2009;16(4):324-329.
88. Haslik W, Kamolz LP, Manna F, et al. Management of full-thickness skin defects in the hand and wrist region: first long-term experiences with the dermal matrix Matriderm. J Plast Reconstr Aesthet Surg. 2010; 63(2):360-364.
89. Healy CM, Boorman JG. Comparison of E-Z Derm and Jelonet dressings for partial skin thickness burns. Burns Incl Therm Inj. 1989; 15(1):52-54.
90. Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil. 2003;24(1):42-48.
91. Helling ER, Dev VR, Garza J, et al. Low fistula rate in palatal clefts closed with the Furlow technique using decellularized dermis. Plast Reconstr Surg. 2006; 117(7):2361-2365.
92. Hirsh F, Berlin SJ, Holtz A. Transdermal oxygen delivery to diabetic wounds: A report of 6 cases. Adv Skin Wound Care. 2009;22(1):20-24.

93. Ho G, Nguyen TJ, Shahabi A, et al. A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. Ann Plast Surg. 2012; 68(4):346-356.
94. Homicz MR, Watson D. Review of injectable materials for soft tissue augmentation. Facial Plast Surg. 2004;20(1):21-29.
95. Hubik DJ, Wasiak J, Paul E, Cleland H. Biobrane: A retrospective analysis of outcomes at a specialist adult burns centre. Burns. 2011;37(4):594-600.
96. Ibrahim AM, Shuster M, Koolen PG, et al. Analysis of the National Surgical Quality Improvement Program database in 19,100 patients undergoing implant-based breast reconstruction: complication rates with acellular dermal matrix. Plast Reconstr Surg. 2013; 132(5):1057-1066.
97. Janfaza M, Martin M, Skinner R. A preliminary comparison study of two noncrosslinked biologic meshes used in complex ventral hernia repairs. World J Surg. 2012;36(8):1760-1764.
98. Jansen DA, Asgari MM, Atillasoy ES, Milstone LM. Clinical and in vitro responses of bilayered skin construct (graftskin) to meshing. Arch Dermatol. 2002;138(6):843-844.
99. Johnson DW, Clark C, Isbel NM, et al.; HONEYPOT Study Group. The honeypot study protocol: A randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int. 2009;29(3):303-309.
100. Jull A, Walker N, Parag V, et al. Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. Br J Surg. 2008; 95(2):175-182.
101. Karr JC, Taddei AR, Picchietti S, et al. A morphological and biochemical analysis comparative study of the collagen products Biopad, Promogram, Puracol, and Colactive. Adv Skin Wound Care. 2011;24(5):208-216.
102. Karr JC. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). Adv Skin Wound Care. 2011; 24(3):119-125.
103. Kathju S, Lasko LA, Medich DS. Perineal hernia repair with acellular dermal graft and suture anchor fixation. Hernia. 2011;15(3):357-360.
104. Kavros S, Dutra T, Gonzalez-Cruz R, et al. The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: A prospective multicenter study. Adv Skin Wound Care. 2014;27(8):356-362.
105. Kavros SJ. Acellular fetal bovine dermal matrix for treatment of chronic ulcerations of the midfoot associated with Charcot neuroarthropathy. Foot Ankle Spec. 2012; 5(4):230-234.
106. Kelechi TJ, Mueller M, Hankin CS, et al. A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in patients with venous leg ulcers. J Am Acad Dermatol. 2011; 66(6):e209-215.

107. Khan ZA, Nambiar A, Morley R, et al. Long-term follow-up of a multicentre randomised controlled trial comparing tension-free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women. BJU Int. 2015; 115(6):968-977.
108. Kim JY, Davila AA, Persing S, et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg. 2012; 129(1):28-41.
109. Kimmel H, Rahn M, Gilbert TW. The clinical effectiveness in wound healing with extracellular matrix derived from porcine urinary bladder matrix: A case series on severe chronic wounds. J Am Col Certif Wound Spec. 2010;2(3):55-59.
110. Kirsner RS, Bohn G, Driver VR, et al. Human acellular dermal wound matrix: Evidence and experience. Int Wound J. 2015;12(6):646-654.
111. Kirsner RS, Fastenau J, Falabella A, et al. Clinical and economic outcomes with graftskin for hard-to-heal venous leg ulcers: A single-center experience. Dermatol Surg. 2002;28(1):81-82.
112. Kirsner RS, Warriner R, Michela M, et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010;146(8):857-862.
113. Koike T, Yasuo M, Shimane T, et al. Cultured epithelial grafting using human amniotic membrane: The potential for using human amniotic epithelial cells as a cultured oral epithelium sheet. Arch Oral Biol. 2011;56(10):1170-1176.
114. Krezdorn N, Könneker S, Paprottka FJ, et al. Biobrane versus topical agents in the treatment of adult scald burns. Burns. 2016 Aug 6.
115. Kulig KM, Luo X, Finkelstein EB, et al. Biologic properties of surgical scaffold materials derived from dermal ECM. Biomaterials. 2013;34(23):5776-5784.
116. Kumar RJ, Kimble RM, Boots R, Pegg SP. Treatment of partial-thickness burns: A prospective, randomized trial using Transcyte. ANZ J Surg. 2004;74(8):622-626.
117. Lagus H, Sarlomo-Rikala M, Böhling T, Vuola J. Prospective study on burns treated with Integra®, a cellulose sponge and split thickness skin graft: Comparative clinical and histological study--randomized controlled trial. Burns. 2013;39(8):1577-1587.
118. Lal S, Barrow RE, Wolf SE, et al. Biobrane improves wound healing in burned children without increased risk of infection. Shock. 2000; 14(3):314-318.
119. Landsman A, Rosines E, Houck A, et al. Characterization of a cryopreserved split-thickness human skin allograft - TheraSkin. Adv Skin Wound Care. 2016;29(9):399-406.
120. Landsman AS, Cook J, Cook E, et al. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011; 4(1):29-41.

121. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009;9:115.
122. Lavery LA, Fulmer J, Shebetka KA, et al.; Grafix Diabetic Foot Ulcer Study Group. The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554-560.
123. Lee EI, Chike-Obi CJ, Gonzalez P, et al. Abdominal wall repair using human acellular dermal matrix: a follow-up study. Am J Surg. 2009; 198(5):650-657.
124. Lee EW, Berbos Z, Zaldivar RA, et al. Use of DermaMatrix graft in oculoplastic surgery. Ophthal Plast Reconstr Surg. 2010;26(3):153-154.
125. Lee LF, Porch JV, Spenler W, Garner WL. Integra in lower extremity reconstruction after burn injury. Plast Reconstr Surg. 2008;121(4):1256-1262.
126. Letendre S, LaPorta G, O'Donnell E, et al. Pilot trial of biovance collagen-based wound covering for diabetic ulcers. Adv Skin Wound Care. 2009;22(4):161-166.
127. Li HY, Xiao SC, Zhu SH, et al. Successful treatment of a patient with an extraordinarily large deep burn. Med Sci Monit. 2011;17(4):CS47-CS51.
128. Limpert JN, Desai AR, Kumpf AL, et al. Repair of abdominalwall defects with bovine pericardium. Am J Surg. 2009;198(5):e60-e65.
129. Lin HJ, Spoerke N, Deveney C, Martindale R. Reconstruction of complex abdominal wall hernias using acellular human dermal matrix: a single institution experience. Am J Surg. 2009; 197(5):599-603.
130. Lindford AJ, Kaartinen IS, Virolainen S, Vuola J. Comparison of Suprathel® and allograft skin in the treatment of a severe case of toxic epidermal necrolysis. Burns. 2011;37(7):e67-e72.
131. Lipkin S, Chaikof E, Isseroff Z, Silverstein P. Effectiveness of OrCel™ (bilayered cellular matrix) in healing of neuropathic diabetic foot ulcers: Results of a multi-center pilot trial. Wounds. 2003;15(7):230-236.
132. Lipsky BA, Berendt AR, Cornia PB, et al.; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54:e132-e173.
133. Liu DZ, Mathes DW, Neligan PC, et al. Comparison of outcomes using AlloDerm versus FlexHD for implant-based breast reconstruction. Ann Plast Surg. 2014; 72(5):503-507.
134. Lullove E. Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities. J Am Podiatr Med Assoc. 2012;102(3):233-239.
135. Lund-Nielsen B, Adamsen L, Gottrup F, et al. Qualitative bacteriology in malignant wounds-a prospective, randomized, clinical study to compare the effect of honey and silver dressings. Ostomy Wound Manage. 2011; 57(7):28-36.

136. Marston WA. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices. 2004;1(1):21-31.
137. Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005; 2(2):161-165.
138. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev. 2012;(10):CD006899.
139. Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care. 2016;25(Sup10):S8-S17.
140. Massee M, Chinn K, Lei J, et al. Dehydrated human amnion/chorion membrane regulates stem cell activity in vitro. J Biomed Mater Res B Appl Biomater. 2016;104(7):1495-1503.
141. Matsushima T, Yamaguchi T, Inoue TK, et al. Recurrent trigeminal neuralgia after microvascular decompression using an interposing technique. Teflon felt adhesion and the sling retraction technique. Acta Neurochir (Wien). 2000;142(5):557-561.
142. Maurice SM, Skeete DA. Use of human acellular dermal matrix for abdominal wall reconstructions. Am J Surg. 2009; 197(1):35-42.
143. McCord C, Nahai FR, Codner MA, et al. Use of porcine acellular dermal matrix (Enduragen) grafts in eyelids: a review of 69 patients and 129 eyelids. Plast Reconstr Surg. 2008; 122(4):1206-1213.
144. Mendenhall SD, Anderson LA, Ying J, et al. The BREASTrial: stage I. Outcomes from the time of tissue expander and acellular dermal matrix placement to definitive reconstruction. Plast Reconstr Surg. 2015; 135(1):29e-42e.
145. Michelotti BF, Brooke S, Mesa J, et al. Analysis of clinically significant seroma formation in breast reconstruction using acellular dermal grafts. Ann Plast Surg. 2013; 71(3):274-177.
146. Milstein CF, Akst LM, Hicks MD, et al. Long-term effects of micronized AlloDerm injection for unilateral vocal fold paralysis. Laryngoscope. 2005; 115(9):1691-1696.
147. Min JH, Yun IS, Lew DH, et al. The use of matriderm and autologous skin graft in the treatment of full thickness skin defects. Arch Plast Surg. 2014;41(4):330-336
148. Misra S, Raj PK, Tarr SM, Treat RC. Results of AlloDerm use in abdominal hernia repair. Hernia. 2008; 12(3):247-250.
149. Monllau JC, Gelber PE, Abat F, et al. Outcome after partial medial meniscus substitution with the collagen meniscal implant at a minimum of 10 years' follow-up. Arthroscopy. 2011; 27(7):933-943.

150. Moravvej H, Hormozi AK, Hosseini SN, et al. Comparison of the application of allogeneic fibroblast and autologous mesh grafting with the conventional method in the treatment of third-degree burns. J Burn Care Res. 2016;37(1):e90-e95.
151. Mostaque AK, Rahman KB. Comparisons of the effects of biological membrane (amnion) and silver sulfadiazine in the management of burn wounds in children. J Burn Care Res. 2011; 32(2):200-209.
152. Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (Oasis Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005; 41(5):837-843.
153. Motolese A, Vignati F, Brambilla R, et al. Interaction between a regenerative matrix and wound bed in nonhealing ulcers: Results with 16 cases. Biomed Res Int. 2013;2013:849321.
154. Mulder G, Lee DK. A retrospective clinical review of extracellular matrices for tissue reconstruction: Equine pericardium as a biological covering to assist with wound closure. Wounds. 2009;21(9):254-261.
155. Mulder G, Lee DK. Case presentation: Xenograft resistance to protease degradation in a vasculitic ulcer. Int J Low Extrem Wounds. 2009;8:157.
156. Mulder M, Crosier J, Dunn R. Cauda equina compression by hydrogel dural sealant after a laminotomy and discectomy: Case report. Spine (Phila Pa 1976). 2009;34(4):E144-E148.
157. Munster AM, Weiner SH, Spence RJ. Cultured epidermis for the coverage of massive burn wounds. A single center experience. Ann Surg. 1990;211(6):676-679.
158. Nahabedian MY. Secondary nipple reconstruction using local flaps and AlloDerm. Plast Reconstr Surg. 2005; 115(7):2056-2061.
159. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs. 1997;21(11):1203-1210.
160. Nelson EA, Jones J. Venous leg ulcers. In: BMJ Clinical Evidence. London, UK: BMJ Publishing Group; September 2007.
161. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing Oasis Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005; 18(5 Pt 1):258-266.
162. Noordenbos J, Doré C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil. 1999; 20(4):275-281.
163. O'Donnell TF Jr, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006;44(5):1118-1125.
164. Palaia DA, Arthur KS, Cahan AC, Rosenberg MH. Incidence of Seromas and Infections Using Fenestrated versus Nonfenestrated Acellular Dermal Matrix in Breast Reconstructions. Plast Reconstr Surg Glob Open. 2015; 3(11):e569.

165. Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med. 2002;18(1):77-88, vi.
166. Patel KM, Nahabedian MY, Gatti M, Bhanot P. Indications and outcomes following complex abdominal reconstruction with component separation combined with porcine acellular dermal matrix reinforcement. Ann Plast Surg. 2012 Oct;69(4):394-398.
167. Patel VR, Samavedi S, Bates AS, et al. Dehydrated human amnion/chorion membrane allograft nerve wrap around the prostatic neurovascular bundle accelerates early return to continence and potency following robot-assisted radical prostatectomy: propensity score-matched analysis. Eur Urol. 2015; 67(6):977-980.
168. Peled ZM. Treatment of a patient with small fiber pathology using nerve biopsy and grafting: A case report. J Reconstr Microsurg. 2013;29(8):551-554.
169. Pham C, Greenwood J, Cleland H, et al. Bioengineered skin substitutes for the management of burns: A systematic review. Burns. 2007;33(8):946-957.
170. Prasad JK, Feller I, Thomson PD. A prospective controlled trial of Biobrane versus scarlet red on skin graft donor areas. J Burn Care Rehabil. 1987; 8(5):384-386.
171. Pryor SG, Sykes J, Tollefson TT. Efficacy of fibrin sealant (human) (Evicel) in rhinoplasty: A prospective, randomized, single-blind trial of the use of fibrin sealant in lateral osteotomy. Arch Facial Plast Surg. 2008;10(5):339-344.
172. Pugliese R, Maggioni D, Sansonna F, et al. Efficacy and effectiveness of suture bolster with Seamguard. Surg Endosc. 2009;23(6):1415-1416.
173. Purdue GF, Hunt JL, Still JM Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18(1 Pt 1):52-57.
174. Quarti A, Nardone S, Colaneri M, et al. Preliminary experience in the use of an extracellular matrix to repair congenital heart diseases. Interact Cardiovasc Thorac Surg. 2011; 13(6):569-572
175. Radu CA, Gazyakan E, Germann G, et al. Optimizing Suprathel®-therapy by the use of Octenidine-Gel®. Burns. 2011;37(2):294-298.
176. Rahmanian-Schwarz A, Beiderwieden A, Willkomm LM, et al. A clinical evaluation of Biobrane(®) and Suprathel(®) in acute burns and reconstructive surgery. Burns. 2011;37(8):1343-1348.
177. Rathinam S, Naidu BV, Nanjaiah P, et al. BioGlue and Peri-strips in lung volume reduction surgery: Pilot randomised controlled trial. J Cardiothorac Surg. 2009;4:37.
178. Regulski M, Jacobstein DA, Petranto RD, et al. A retrospective analysis of a human cellular repair matrix for the treatment of chronic wounds. Ostomy Wound Manage. 2013; 59(12):38-43.

179. Renner R, Harth W, Simon JC. Transplantation of chronic wounds with epidermal sheets derived from autologous hair follicles--the Leipzig experience. Int Wound J. 2009;6(3):226-232.
180. Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J. 2009; 6(3):196-208.
181. Reyzelman AM, Bazarov I. Human acellular dermal wound matrix for treatment of DFU: Literature review and analysis. J Wound Care. 2015;24(3):128; 129-134.
182. Rice JB, Desai U, Ristovska L, et al. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers. J Med Econ. 2015;18(8):586-595.
183. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J. 2009;9(8):623-629.
184. Riml S, Wallner H, Larcher L, et al. Aesthetic improvements of skin grafts in nasal tip reconstruction. Aesthetic Plast Surg. 2011; 35(4):475-479.
185. Robb GL, Gurtner GC. Letter to the editor. Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. ePlasty. 2016;16:229.
186. Rodkey, WG, DeHaven KE, Montgomery WH 3rd, et al. Comparison of the collagen meniscus implant with partial meniscectomy. A prospective randomized trial. J Bone Joint Surg Am. 2008; 90(7):1413-1426.
187. Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J. 2007;4(1):3-7.
188. Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care. 2010;23(1):34-38.
189. Romanelli M, Dini V, Vowden P, Agren MS. Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: Experimental and clinical evidence. Clin Interv Aging. 2008;3(2):263-272.
190. Roth JS, Brathwaite C, Hacker K, et al. Complex ventral hernia repair with a human acellular dermal matrix. Hernia.2015;19(2):247-252.
191. Rundell VL, Beck RT, Wang CE, et al. Complication prevalence following use of tutoplast-derived human acellular dermal matrix in prosthetic breast reconstruction: a retrospective review of 203 patients. J Plast Reconstr Aesthet Surg. 2014; 67(10):1345-1351.

192. Ryan CM, Schoenfeld DA, Malloy M, et al. Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. J Burn Care Rehabil. 2002;23(5):311-317.
193. Ryssel H, Germann G, Riedel K, et al. Suprathel-acetic acid matrix versus acticoat and aquacel as an antiseptic dressing: An in vitro study. Ann Plast Surg. 2010;65(4):391-395.
194. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: One center's experience. Dermatol Surg. 2002;28(8):698-703.
195. Sanders L, Landsman AS, Landsman A, et al. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage. 2014; 60(9):26-38.
196. Schwarze H, Küntscher M, Uhlig C, et al. Suprathel, a new skin substitute, in the management of donor sites of split-thickness skin grafts: Results of a clinical study. Burns. 2007;33(7):850-854.
197. Serena TE, Carter MJ, Le LT, et al.; EpiFix VLU Study Group. A multi-center randomized controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014; 22(6):688-693
198. Sergent F, Resch B, Loisel C, et al. Mid-term outcome of laparoscopic sacrocolpopexy with anterior and posterior polyester mesh for treatment of genito-urinary prolapse. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):217-222.
199. Shah BC, Tiwari MM, Goede MR, et al. Not all biologics are equal! Hernia. 2011;15(2):165-171.
200. Shah SS, Todkar JS, Shah PS. Buttressing the staple line: A randomized comparison between staple-line reinforcement versus no reinforcement during sleeve gastrectomy. Obes Surg. 2014;24(12):2014-2020.
201. Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2014; 11(6):711-717.
202. Skovgaard C, Holm B, Troelsen A, et al. No effect of fibrin sealant on drain output or functional recovery following simultaneous bilateral total knee arthroplasty: A randomized, double-blind, placebo-controlled study. Acta Orthop. 2013;84(2):153-158.
203. Smith T, Legel K, Hanft JR. Topical Leptospermum honey (Medihoney) in recalcitrant venous leg wounds: A preliminary case series. Adv Skin Wound Care. 2009;22(2):68-71.
204. Sobti N, Liao EC. Surgeon-controlled study and meta-analysis comparing FlexHD and AlloDerm in immediate breast reconstruction outcomes. Plast Reconstr Surg. 2016;138(5):959-967.

205. Solomon MP, Komlo C, Defrain M. Allograft materials in phalloplasty: A comparative analysis. Ann Plast Surg. 2013;71(3):297.
206. Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. 2010; 100(1):73-77.
207. Strauch JT, Spielvogel D, Lansman SL, et al. Long-term integrity of teflon felt-supported suture lines in aortic surgery. Ann Thorac Surg. 2005;79(3):796-800.
208. Swan J. Use of cryopreserved, particulate human amniotic membrane and umbilical cord (AM/UC) tissue: A case series study for application in the healing of chronic wounds. Surg Technol Int. 2014;25:73-78.
209. Tamhane A, Vajpayee RB, Biswas NR, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. Ophthalmology. 2005; 112(11):1963-1969.
210. Tausche AK, Skaria M, Böhlen L, et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen. 2003;11(4):248-252.
211. Tenenhaus M, Bhavsar D, Rennekampff HO. Treatment of deep partial thickness and indeterminate depth facial burn wounds with water-jet debridement and a biosynthetic dressing. Injury. 2007;38 Suppl 5:S39-S45.
212. Tenholder M, Davids JR, Gruber HE, Blackhurst DW. Surgical management of juvenile amputation overgrowth with a synthetic cap. J Pediatr Orthop. 2004;24(2):218-226.
213. Thamboo A, Thamboo A, Philpott C, et al. Single-blind study of manuka honey in allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg. 2011;40(3):238-243.
214. Topol BM, Dalton EF, Ponn T, et al. Immediate single-stage breast reconstruction using implants and human acellular dermal tissue matrix with adjustment of thelower pole of the breast to reduce unwanted lift. Ann Plastic Surg. 2008;61(5):494-499.
215. Uhlig C, Rapp M, Hartmann B, et al. Suprathel-an innovative, resorbable skin substitute for the treatment of burn victims. Burns. 2007;33(2):221-229.
216. Vanstraelen P. Comparison of calcium sodium alginate (KALTOSTAT) and porcine xenograft (E-Z DERM) in the healing of split-thickness skin graft donor sites. Burns. 1992; 18(2):145-148
217. Venturi ML, Mesbahi AN, Boehmler JH 4th, Marrogi AJ. Evaluating sterile human acellular dermal matrix in immediate expander-based breast reconstruction: a multicenter, prospective, cohort study. Plast Reconstr Surg. 2013; 131(1):9e-18e.
218. Veves A, Falanga V, Armstrong DG, Sabolinski ML.; Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic

diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24(2):290-295.

219. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137(7):822-827.

220. Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound Care. 2002;11(9):335-341.

221. Vloemans AF, Hermans MH, van der Wal MB, et al. Optimal treatment of partial thickness burns in children: A systematic review. Burns. 2014;40(2):177-190.

222. Walters J, Cazzell S, Pham H, et al. Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. Eplasty. 2016;16:e10.

223. Wangensteen KJ, Kalliainen LK. Collagen tube conduits in peripheral nerve repair: a retrospective analysis. Hand (N Y). 2010; 5(3):273-277.

224. Ward KC, Costello KP, Baalman S, et al. Effect of acellular human dermis buttress on laparoscopic hiatal hernia repair. Surg Endosc. 2015;29(8):2291-2297.

225. Waymack P, Duff RG, Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. Burns. 2000; 26(7):609-619.

226. Weinstein JS, Liu KC, Delashaw JB Jr, et al, The safety and effectiveness of a dural sealant system for use with nonautologous duraplasty materials. J Neurosurg. 2010;112(2):428-433.

227. Wiegmann B, Zardo P, Dickgreber N, et al. Biological materials in chest wall reconstruction: Initial experience with the Peri-Guard Repair Patch. Eur J Cardiothorac Surg. 2010;37(3):602-605.

228. Willett NJ, Thote T, Lin AS, et al. Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development. Arthritis Res Ther. 2014;16(1):R47.

229. Williams ML, Holewinski JE. Use of a human acellular dermal wound matrix in patients with complex wounds and comorbidities. J Wound Care. 2015;24(6):261-262, 264-267.

230. Wollina U, Schmidt WD, Krönert C, et al. Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: Preliminary observations. Int J Low Extrem Wounds. 2005;4(4):214-224.

231. Woo KY, Coutts PM, Sibbald RG. Continuous topical oxygen for the treatment of chronic wounds: A pilot study. Adv Skin Wound Care. 2012;25(12):543-547.

232. Yanagawa B, Rao V, Yau TM, Cusimano RJ. Initial experience with intraventricular repair using CorMatrix extracellular matrix. Innovations (Phila). 2013;8(5):348-352.
233. Yanagawa B, Rao V, Yau TM, Cusimano RJ. Potential myocardial regeneration with CorMatrix ECM: A case report. J Thorac Cardiovasc Surg. 2014;147(4):e41-e43.
234. Yao M, Attalla K, Ren Y, et al. Ease of use, safety, and efficacy of integra bilayer wound matrix in the treatment of diabetic foot ulcers in an outpatient clinical setting: A prospective pilot study. J Am Podiatr Med Assoc. 2013;103(4):274-280.
235. Yeen WC, Faber C, Caldeira C, et al. Reconstruction of pulmonary venous conduit with CorMatrix in lung transplant. Asian Cardiovasc Thorac Ann. 2013;21(3):360-362.
236. Yu S, Jastrow K, Clapp B, et al. Foreign material erosion after laparoscopic Roux-en-Y gastric bypass: Findings and treatment. Surg Endosc. 2007;21(7):1216-1220.
237. Zaffagnini S, Marcheggiani Muccioli GM, et al. Prospective long-term outcomes of the medial collagen meniscus implant versus partial medial meniscectomy: a minimum 10-year follow-up Study. Am J Sports Med. 2011; 39(5):977-985.
238. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-98.
239. Zelen CM, Gould L, Serena TE, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724-732.
240. Zelen CM, Poka A, Andrews J. Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis--a feasibility study. Foot Ankle Int. 2013;34(10):1332-1339.
241. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014;11(2):122-128.
242. Zhong T, Janis JE, Ahmad J, Hofer SO. Outcomes after abdominal wall reconstruction using acellular dermal matrix: a systematic review. J Plast Reconstr Aesthet Surg. 2011; 64(12):1562-1571.
243. Zhong T, Temple-Oberle C, Hofer S, et al.; MCCAT Study Group. The Multi Centre Canadian Acellular Dermal Matrix Trial (MCCAT): study protocol for a randomized controlled trial in implant-based breast reconstruction. Trials. 2013; 14:356.

Clinical Guideline Revision / History Information

Original: Review/Revise Dates	**Approval Signature/ Title**
Original Date: Reviewed/Revised: Signed:	7/31/2017 Sean Martin, MD